Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

Biohaven Ltd.

BHVNNYSEEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 12:57 PM ESTFiling CIK 1935979Accession 0001274173-26-000262
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
BIOHAVEN LTD.
Company CIK
0001935979
Street
215 CHURCH STREET
City
NEW HAVEN
State / country code
CT
Postal code
06510

Statement details

Amendment number
4
Security class
Common Shares
Event date
09/30/2026
Rule designation
Rule 13d-1(b)

Reporting person 1

Name
JANUS HENDERSON GROUP Ltd.
Citizenship / organization
Y9
Reporting person type
HC
Aggregate amount owned
2,036,197
Percent of class
1.4
Sole voting power
0
Shared voting power
2,036,197
Sole dispositive power
0
Shared dispositive power
2,036,197

Item 1

Issuer

BIOHAVEN LTD.

Principal executive office address

215 CHURCH STREET NEW HAVEN, CT 06510

Item 2

Citizenship

Y9

Filing person

Janus Henderson Group Ltd. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Janus Henderson Group Ltd. It does not include securities, if any, beneficially owned by Janus Henderson Group Ltd.s ultimate parent Janus Henderson Group Holdings, LLC, the direct or indirect owners of Janus Henderson Group Holdings, LLC, or other persons that may be deemed under control of such owners. Any beneficial ownership by such persons has been disaggregated from that of Janus Henderson Group Ltd. in accordance with the release.

Principal business or residence address

201 Bishopsgate EC2M 3AE, United Kingdom

Item 3

Not applicable indication

N

Type of filing person

HC

Item 4

Percent of class

1.4

Amount beneficially owned

Janus Henderson Group Ltd. (JHG) is the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents thereof, including but not limited to Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, Janus Henderson Investors Australia Institutional Funds Management Limited, Janus Henderson Investors Middle East Limited, Janus Henderson Investors (Jersey) Limited, Janus Henderson Investors (Japan) Limited, Janus Henderson Investors (Singapore) Limited, Kapstream Capital Pty Limited, Privacore Capital Advisors LLC, Tabula Investment Management Limited, Victory Park Capital Advisors LLC, and Richard Berstein Advisors LLC (each, an Asset Manager and together, the Asset Managers). The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios). As a result of their exercise of investment and/or voting discretion on behalf of the Managed Portfolios, the Asset Managers may be deemed to be the beneficial owner of 2,036,197 common shares of Biohaven Ltd. However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.

Sole voting power

0

Shared voting power

2036197

Sole dispositive power

0

Shared dispositive power

2036197

Item 5

Not applicable indication

Y

Ownership of 5% or less

N

Item 6

Not applicable indication

N

Ownership on behalf of another person

The Managed Portfolios have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts. Of the Managed Portfolios, none own more than five percent of the common shares of Biohaven Ltd.

Item 7

Not applicable indication

N

Subsidiaries

Please refer to Exhibit 99.

Item 8

Not applicable indication

N

Group members

N/A

Item 9

Not applicable indication

N

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Exhibits

Exhibit 24: Power of Attorney Exhibit 99: Item 7

Signature 1

Reporting person
JANUS HENDERSON GROUP Ltd.
Signed
Kristin Mariani
Title
Head of North America Compliance
Date
11/16/2026

Filed exhibits

Company context

Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience, and oncology. The Company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; and myostatin inhibition for neuromuscular and metabolic diseases, including obesity.

Current securities

Recent company filings

  1. Regulation FD DisclosureNov 16, 2026
  2. Results of Operations and Financial ConditionOct 29, 2026
  3. 10-Q filingOct 29, 2026
  4. Regulation FD DisclosureOct 22, 2026
  5. Entry into a Material Definitive Agreement · Regulation FD DisclosureOct 15, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.